Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Events

10 Feb 2026 - 13 Feb 2026
17 Apr 2026 - 21 Apr 2026

High Cell-Free DNA Integrity Is a Biomarker for Poor Breast Cancer Survival

By LabMedica International staff writers
Posted on 12 Oct 2021
A team of Finnish researchers has refined a liquid biopsy analysis technique to act as a more specific biomarker in order to more accurately predict poor prognosis for patients with aggressive breast cancer.

Breast cancer (BC) research has focused lately on the utilization of cell-free DNA (cfDNA) and its concentration (cfDConc) and integrity (cfDI) as potential biomarkers. More...
The cfDI describes the ratio of large and small cfDNA fragments. While the association of cfDConc and poor survival has already been recognized, studies on the prognostic value of cfDI have had contradictory results.

To clarify the situation, investigators at the University of Eastern Finland (Kuopio, Finland) evaluated the prognostic potential of cfDConc and cfDI in Eastern Finnish BC cases with a non-metastatic disease.

For this study, the investigators selected 204 Eastern Finnish BC cases with non-metastatic disease and isolated cfDNA from the serum collected at the time of diagnosis before any treatment was given. The cfDConc and cfDI were measured with a fluorometer and electrophoresis, and the results were analyzed together with 25 years of survival data from the Kuopio Breast Cancer Project (KBCP), which was initiated in the 1990s.

Results revealed that high cfDConc was not an independent prognostic factor, while high cfDI was found to be an independent prognostic factor for poor overall survival (OS) and breast cancer-specific survival (BCSS). Inclusion of cfDI in the commonly used multivariate logistic regression model improved the predictive performance.

The results showing that high cfDI was an independent prognostic factor for poor OS and BCSS and improved the predictive performance of logistic regression models demonstrated its prognostic potential.

“Our results show that together with traditional prognostic factors, measuring the integrity of cfDNA can in the future help us to identify breast cancer patients with a poor prognosis earlier and more accurately than before. This would allow patients requiring more intensive care to be placed under intensified care and monitoring earlier,” said senior author Dr. Arto Mannermaa, professor of clinical medicine at the University of Eastern Finland.

The study was published in the September 18, 2021, online edition of the journal Cancers.

Related Links:
University of Eastern Finland


Gold Member
Blood Gas Analyzer
Stat Profile pHOx
POC Helicobacter Pylori Test Kit
Hepy Urease Test
CBM Analyzer
Complete Blood Morphology (CBM) Analyzer
Autoimmune Liver Diseases Assay
Microblot-Array Liver Profile Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.